WO2001074331A1 - Compositions huileuses contenant des medicaments solubles dans des graisses - Google Patents

Compositions huileuses contenant des medicaments solubles dans des graisses Download PDF

Info

Publication number
WO2001074331A1
WO2001074331A1 PCT/JP2001/002621 JP0102621W WO0174331A1 WO 2001074331 A1 WO2001074331 A1 WO 2001074331A1 JP 0102621 W JP0102621 W JP 0102621W WO 0174331 A1 WO0174331 A1 WO 0174331A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
soluble drugs
chain fatty
compositions containing
oily compositions
Prior art date
Application number
PCT/JP2001/002621
Other languages
English (en)
French (fr)
Inventor
Yoshitaka Nishihara
Haruki Kinoshita
Takayoshi Yoshikawa
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Priority to AU2001244614A priority Critical patent/AU2001244614A1/en
Priority to EP01917589A priority patent/EP1273287A1/en
Priority to MXPA02009763A priority patent/MXPA02009763A/es
Priority to JP2001572076A priority patent/JP3831253B2/ja
Priority to CA002404381A priority patent/CA2404381A1/en
Publication of WO2001074331A1 publication Critical patent/WO2001074331A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
PCT/JP2001/002621 2000-04-04 2001-03-29 Compositions huileuses contenant des medicaments solubles dans des graisses WO2001074331A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001244614A AU2001244614A1 (en) 2000-04-04 2001-03-29 Oily compositions containing highly fat-soluble drugs
EP01917589A EP1273287A1 (en) 2000-04-04 2001-03-29 Oily compositions containing highly fat-soluble drugs
MXPA02009763A MXPA02009763A (es) 2000-04-04 2001-03-29 Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa.
JP2001572076A JP3831253B2 (ja) 2000-04-04 2001-03-29 高脂溶性化合物を含有する油性組成物
CA002404381A CA2404381A1 (en) 2000-04-04 2001-03-29 Oily compositions containing highly fat-soluble drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000102272 2000-04-04
JP2000-102272 2000-04-04

Publications (1)

Publication Number Publication Date
WO2001074331A1 true WO2001074331A1 (fr) 2001-10-11

Family

ID=18616188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002621 WO2001074331A1 (fr) 2000-04-04 2001-03-29 Compositions huileuses contenant des medicaments solubles dans des graisses

Country Status (9)

Country Link
US (1) US20030149061A1 (ja)
EP (1) EP1273287A1 (ja)
JP (1) JP3831253B2 (ja)
KR (1) KR20030009416A (ja)
CN (1) CN1431896A (ja)
AU (1) AU2001244614A1 (ja)
CA (1) CA2404381A1 (ja)
MX (1) MXPA02009763A (ja)
WO (1) WO2001074331A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005075804A (ja) * 2003-09-03 2005-03-24 Toyo Capsule Kk メナテトレノン含有医薬組成物
US7053088B2 (en) 2002-05-22 2006-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7144888B2 (en) 2002-08-08 2006-12-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7511044B2 (en) 2004-02-11 2009-03-31 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2009513642A (ja) * 2005-10-25 2009-04-02 アボット・ラボラトリーズ 低水溶解度の薬剤を含む製剤およびそれの使用方法
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
JP2016174550A (ja) * 2015-03-19 2016-10-06 日清オイリオグループ株式会社 食用油脂

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
EP1809614B1 (en) * 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
MX2007011500A (es) * 2005-03-16 2007-11-21 Targegen Inc Compuestos pirimidina y metodos de uso.
JP2008543775A (ja) * 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
BR122021011787B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US20100273852A1 (en) * 2006-11-09 2010-10-28 Takeda Pharmaceutical Company Limited Pharmaceutical composition
ES2559008T3 (es) * 2009-05-11 2016-02-10 Nestec S.A. Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios
ES2575215T3 (es) 2009-12-11 2016-06-27 Autifony Therapeutics Limited Derivados de imidazolidindiona
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
BR112013013914B1 (pt) 2010-12-06 2021-10-26 Autifony Therapeutics Limited Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
CN103596943B (zh) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
WO2013175211A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
BR112014028991A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd triazóis como inibidores de kv3
MA38661A1 (fr) 2013-06-27 2017-03-31 Pfizer Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
WO2017158427A1 (en) * 2016-03-14 2017-09-21 Team Foods Colombia S.A. Composition and method for treatment of cognitive impairment
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5329916A (en) * 1976-08-31 1978-03-20 Yamanouchi Pharmaceut Co Ltd Ready absorption oryzanol preparation
US5504105A (en) * 1990-03-23 1996-04-02 Chinoin Pharmaceutical And Chemical Works Co. Ltd. Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
JPH0892088A (ja) * 1994-09-16 1996-04-09 Shionogi & Co Ltd 経口投与用油性組成物
WO1997039999A1 (fr) * 1996-04-22 1997-10-30 Shionogi & Co., Ltd. Nouveaux composes de terphenyl et medicaments contenant ces composes
WO1998004508A1 (en) * 1996-07-31 1998-02-05 Shionogi & Co., Ltd. NOVEL p-TERPHENYL COMPOUNDS
WO1999038829A1 (fr) * 1998-01-28 1999-08-05 Shionogi & Co., Ltd. Nouveau compose tricyclique
EP0953359A1 (en) * 1996-12-19 1999-11-03 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
AU4540693A (en) * 1992-06-25 1994-01-24 G.D. Searle & Co. Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5329916A (en) * 1976-08-31 1978-03-20 Yamanouchi Pharmaceut Co Ltd Ready absorption oryzanol preparation
US5504105A (en) * 1990-03-23 1996-04-02 Chinoin Pharmaceutical And Chemical Works Co. Ltd. Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
JPH0892088A (ja) * 1994-09-16 1996-04-09 Shionogi & Co Ltd 経口投与用油性組成物
WO1997039999A1 (fr) * 1996-04-22 1997-10-30 Shionogi & Co., Ltd. Nouveaux composes de terphenyl et medicaments contenant ces composes
WO1998004508A1 (en) * 1996-07-31 1998-02-05 Shionogi & Co., Ltd. NOVEL p-TERPHENYL COMPOUNDS
EP0953359A1 (en) * 1996-12-19 1999-11-03 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration
WO1999038829A1 (fr) * 1998-01-28 1999-08-05 Shionogi & Co., Ltd. Nouveau compose tricyclique

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053088B2 (en) 2002-05-22 2006-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7396831B2 (en) 2002-05-22 2008-07-08 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7524874B2 (en) 2002-05-22 2009-04-28 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7144888B2 (en) 2002-08-08 2006-12-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7148221B2 (en) 2002-08-08 2006-12-12 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7332511B2 (en) 2002-08-08 2008-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2005075804A (ja) * 2003-09-03 2005-03-24 Toyo Capsule Kk メナテトレノン含有医薬組成物
US8227469B2 (en) 2004-02-11 2012-07-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7511044B2 (en) 2004-02-11 2009-03-31 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
JP2009513642A (ja) * 2005-10-25 2009-04-02 アボット・ラボラトリーズ 低水溶解度の薬剤を含む製剤およびそれの使用方法
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US8415345B2 (en) 2008-05-06 2013-04-09 Glaxo SmithKline LLC Benzene sulfonamide thiazole and oxazole compounds
US8642759B2 (en) 2008-05-06 2014-02-04 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
US9233956B2 (en) 2008-05-06 2016-01-12 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
JP2016174550A (ja) * 2015-03-19 2016-10-06 日清オイリオグループ株式会社 食用油脂

Also Published As

Publication number Publication date
CA2404381A1 (en) 2002-09-26
EP1273287A1 (en) 2003-01-08
JP3831253B2 (ja) 2006-10-11
AU2001244614A1 (en) 2001-10-15
US20030149061A1 (en) 2003-08-07
KR20030009416A (ko) 2003-01-29
MXPA02009763A (es) 2003-03-27
CN1431896A (zh) 2003-07-23

Similar Documents

Publication Publication Date Title
WO2001074331A1 (fr) Compositions huileuses contenant des medicaments solubles dans des graisses
NZ512287A (en) Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
SI9500350B (sl) Oralni multipli emulzijski predkoncentrat
EP1253142A4 (en) COMPOUNDS HAVING AGONISM AGAINST THE THROMBOPOIETIN RECEPTOR
FI20000170A (fi) Itse-emulgoituva valmiste lipofiilisia yhdisteitä varten
PT999838E (pt) Formulacao auto-emulsionante para compostos lipofilicos
AR010634A1 (es) Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
WO2001054501A3 (en) Herbicidal composition
WO2000037057A3 (en) Novel formulations comprising lipid-regulating agents
NO955352L (no) Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse
TR199701281A3 (tr) Pestisidal bilesim.
KR950017949A (ko) 벤조티오펜 화합물과 수용성 사이클로덱스트린의 수용성 내포착물, 및 그의 약학제제 및 제조 방법
CO4970826A1 (es) Preparaciones de capsula suave que contienen ciclosporina
WO2002024623A3 (en) Novel alkanoic acid derivatives
NZ330062A (en) composition containing cyclosporin, propylene carbonate, an oil component and a surfactant
NO20014119L (no) Medikament inneholdende et sulfopyranosylacylglycerolderivat
EA200300481A1 (ru) Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов
ATE251382T1 (de) Dithiocarbamat-flüssigformulierungen
WO2000051589A3 (en) VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF
EP1084693A4 (en) ALPHA-HYDROXY FATTY ACID DERIVATIVES AND COMPOSITION BASED ON SUCH DERIVATIVES FOR EXTERNAL USE
EP1510511A4 (en) GINGEROL ANALOGS AND THEIR USE
EP0598117A4 (en) BENZOPYRANE DERIVATIVE AND ANTI-ALLERGIC CONTAINING THIS AS AN ACTIVE COMPONENT.
WO2000007580A3 (en) Pharmaceutical compositions against autoimmune diseases
CA2054738A1 (en) 15-deoxyprostaglandin derivatives
PE59499A1 (es) Composicion farmaceutica de ciclosporina

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001244614

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2404381

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027013220

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009763

Country of ref document: MX

Ref document number: 10240602

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001917589

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 01810584X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001917589

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027013220

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001917589

Country of ref document: EP